Acquired Company

Novartis acquired MorphoSys AG for €68 per share in cash, with a total equity value of €2.7 billion, and the acquisition was completed on May 23, 2024.

MorphoSys AG (ADR) is a prominent biopharmaceutical company based in Planegg, Germany, specializing in the development and commercialization of innovative therapeutic antibodies targeting cancer and autoimmune diseases. Leveraging its proprietary technology platforms, the company has cultivated a robust pipeline of novel antibody-based therapies designed to meet significant unmet medical needs. With a strategic focus on expanding its presence in the U.S. market alongside global initiatives, MorphoSys is well-positioned to advance treatment paradigms and drive innovation in the dynamic biotechnology sector. Show more

Location: SEMMELWEISSTRASSE 7, PLANEGG, GERMANY, 82152, Bayern, 82152, USA | Website: https://www.morphosys.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.856B

52 Wk Range

$0.00 - $0.00

Previous Close

$18.96

Open

$18.96

Volume

N/A

Day Range

$18.96 - $18.96

Enterprise Value

0.00

Cash

131.3M

Avg Qtr Burn

-64.43M

Insider Ownership

0.00%

Institutional Own.

7.44%

Qtr Updated

03/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tremfya (guselkumab) (IL-23) Details Psoriatic arthritis, Plaque psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Monjuvi (Tafasitamab) (CD19) Details B-cell malignancies, Diffuse large B cell lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelabresib (CPI-0610) + ruxolitinib Details Myelofibrosis, Cancer, Bone marrow cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gantenerumab Details Alzheimer's disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tafasitamab (CD19) Details Cancer, B-cell malignancies, B-cell lymphoma, Diffuse large B cell lymphoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tulmimetostat /CPI-0209 (EZH2 inhibitor) Details Cancer, Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.